Status:
COMPLETED
Feasibility Study of the AblaCare System in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With Infertility Due to Polycystic Ovary Syndrome
Lead Sponsor:
May Health
Conditions:
Polycystic Ovary Syndrome
Infertility, Female
Eligibility:
FEMALE
18-40 years
Phase:
NA
Brief Summary
The objective of the study is to provide preliminary evidence for the safety and effectiveness of the AblaCare System in transvaginal ablation of ovarian tissue under ultrasound visualization in women...
Eligibility Criteria
Inclusion
- Age: ≥ 18 to ≤ 40 years
- Diagnosis of Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria: Infertility associated with chronic anovulation or oligomenorrhea, AND EITHER:
- 1. Ultrasonographic evidence of PCOS (ovarian volume ≥ 10ml and/or ovarian antral follicle count per ovary ≥ 20) OR 2.2. Evidence of hyperandrogenaemia: either clinical (hirsutism defined as mFG level ≥ 4-6 depending on ethnicity) or biochemical (raised serum concentration of androgens (testosterone ≥ 2.5nmol/l, or FAI \> 4)
- At least one ovary with ovarian volume ≥ 10ml
- Ovarian accessibility: determined by ability to bring transvaginal ultrasound transducer into close proximity to ovaries
- Failure to respond to first-line pharmacological treatment or is contraindicated for or decline such treatment.
- At least one patent fallopian tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years
- Willing to comply with Clinical Investigation Plan-specified follow-up evaluation
- Ability to understand study requirements and has sufficient fluency in one of the IRB-approved written translation of the Patient Information and Informed consent form
- Signed informed consent
- Normal sperm parameters based on WHO 2010 criteria (concentration ≥ 15 million/mL, total motility ≥ 40%, normal morphology ≥ 4%) within the last year
- Ability to have regular vaginal intercourse during the study
- No previous sterilization procedures (vasectomy, tubal ligation) that have been reversed
Exclusion
- Current pregnancy
- Marked obesity, BMI \> 40
- Marked hyperandrogenism (FAI \> 15)
- Patient is currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study
- Patient not willing to stop all concomitant first-line oral medications at least 6 weeks prior to study procedure and until the 3-month endpoint is reached, and all other forms of ovulation-induction treatment until the 6-month endpoint is reached
- Lack of capacity to give informed consent
- Lack of capacity to follow Clinical Investigation Plan and study requirements including all study follow-up visits
- Previous ovarian surgery: laparoscopic ovarian drilling, endometriosis surgery, ovarian cysts surgery
- Patient with known or suspected periovarian adhesions
- Transvaginal ultrasound transducer cannot be brought into proximity of both ovaries
Key Trial Info
Start Date :
May 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 11 2023
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT05320289
Start Date
May 12 2022
End Date
October 11 2023
Last Update
November 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73104